INTRODUCTION
The neurotrophins, a family of polypeptide growth factors, exert their diverse functions in the developing and the mature nervous system, including neuronal survival and death. These molecules include nerve growth factor (NGF), brain-derived growth factor (BDNF), and the NT3, 4/5, 6, and 7 neurotrophins (1) . Two different classes of proteins have been identified as receptors for neurotrophin: the high affinity tyrosine kinase Trk receptors including TrkA, TrkB, and TrkC and the low affinity neurotrophin receptor p75 (p75NTR). BDNF is one of the most well characterized neurotrophins. In addition to promotion of cell survival and axonal outgrowth, BDNF and its receptor TrkB regulates the dendritic morphology and synapse formation.
Shc family adaptors function downstream of receptor tyrosine kinases (RTKs), including Trk receptors. They can be phosphorylated and form stable associations with activated RTKs through their PTB or SH2 domains. To date, four members of the Shc family have been identified and designated as ShcA (also called Shc), ShcB (also called Sck or Sli), ShcC (also called N-Shc or Rai) and ShcD (also called RalP) (2, 3) .
All Shc family members characterized are modular docking proteins consisting of a central glycine/proline-rich region homologous to the α1 chain of collagen (CH1) with a C-terminal SH2 domain and an N-terminal PTB domain. In addition, a second N-terminal proline-rich collagen homology region (CH2) is present in the longest isoform of p66ShcA, in p64ShcC, in p68ShcB and in p69ShcD (4) . The CH2 region mediates binding to Src homology 3 (SH3) domain-containing proteins (5) .
Although sharing high similarity in their sequence, especially in their PTB and SH2 domains, Shc family members are differentially expressed. In the nervous system, ShcA is mainly expressed in neural stem cells but not in mature brains. In contrast, ShcB and ShcC are distributed in a wide range of structures in the adult brain (6) . Similar to ShcB and ShcC, ShcD is broadly expressed in mature mouse brain. ShcD has also been found expressed in skeletal muscle and associates with Musk (2). Additionally, ShcD is located in human melanoma cells and involved in metastasis of melanoma cells (3) .
The biological function of ShcD is largely unknown. Here we report that ShcD is a substrate of TrkB and it regulates BDNF induced MAPK signaling pathway. This protein is, thus, a new mediator of neurotrophin signaling and probably play an important role in neural development and differentiation.
RESULTS

ShcD binds directly to the TrkB receptor in a phosphorylationdependent manner
The identification of substrates for neurotrophin receptors is fundamental to understanding the function of neurotrophins. Previously we have reported that the PTB-containing adaptor protein Dok5 is a substrate of TrkB/C, but not TrkA (7). The newly revealed ShcD is highly expressed in adult mouse brain, and spot peptide array suggests that ShcD PTB domain is capa-http://bmbreports.org ble of binding a number of RTK members (8) . To determine whether there are direct protein-protein interactions between full-length ShcD and TrkB, we used yeast two-hybrid system and mammalian cell transfection.
In yeast two-hybrid assay, we observed an interaction between TrkB and ShcD and this interaction was dependent on the catalytic activity of TrkB since a mutation in the ATP binding site (K572A) of the TrkB kinase domain abolished the TrkB-ShcD binding (Fig. 1A) .
To confirm the results in yeast two-hybrid assay, we proceeded to examine their association in transfected 293T cells. Upon BDNF stimulation, wild type TrkB receptor became highly phosphorylated comparing with the kinase dead mutant TrkBM1 (K572A) (Fig 1B, lower panel) . Consistent with this observation, western blot analysis showed that ShcD co-immunoprecipitated with only wild type TrkB, but not TrkBM1 (Fig. 1B, upper panel) .
Next, we detected whether ShcD can colocalize with TrkB in vivo. As shown in Fig. 1C , pEGFP-ShcD significantly colocalized with pmRFP-TrkB throughout the cytoplasm and in the plasma membrane. The kinase dead mutant TrkBM1 is also distributed in the plasma membrane and cytoplasm, however, ShcD is not colocalized so well with TrkBM1 as TrkB in 293T cells.
The in vivo and in vitro systems therefore demonstrate that ShcD directly binds to TrkB in a phosphorylation-dependent manner.
ShcD PTB and SH2 domains bind TrkB in vivo and in vitro
To map the TrkB binding region on ShcD, truncated forms of ShcD containing the CH2, PTB, CH1 or SH2 domain were constructed and yeast two-hybrid assay was performed. In the β-galactosidase activity assays, both the PTB and SH2 domains, but neither the CH2 nor CH1 domain, interacted with TrkB (Fig. 2B) . The interaction between ShcD and TrkC was also performed in yeast two-hybrid assay. The results were similar to that between ShcD and TrkB, showing that both PTB and SH2 domains of ShcD were involved in ShcD-TrkC interaction (9). These results were unexpected since the interaction between ShcA/B/C and Trk receptor is mediated by PTB domain but not SH2 domain (10, 11) .
To further define the binding ability of ShcD PTB and SH2 domains to TrkB receptor, we employed GST pull-down assay. The results are consistent with those obtained in yeast two-hybrid assay, showing that ShcD PTB and SH2 domains can bind to the activated TrkB receptors (Fig. 2C) . Collectively, these data indicate that TrkB binds to both the PTB and SH2 domains of ShcD.
The PTB domain of ShcD associates with TrkB at the juxtamembrane NPQY motif
It is well documented that the classical NPQY sequence of Trk http://bmbreports.org BMB reports . 3A) were assayed in an yeast two-hybrid assay. The results in Fig. 3B showed that the Y516F mutant (M2) lost its ability to interact with ShcD while other tyrosine mutants had no effect on this association, indicating that NPQY motif is indeed the binding site for ShcD PTB domain. In agreement with Fig. 1 , the kinase inactive TrkBM1 (K572A) was unable to bind to ShcD PTB either, suggesting that the kinase activity is essential for their interaction. Similar results were also obtained from GST pull-down assay, showing that TrkBM2 (Y516F) mutant disrupted ShcD PTB binding to TrkB, while the unrelated tyrosine mutation, TrkBM6 (Y817F), did not affect their association (Fig. 3C ). TrkBM2 can abolish the binding of TrkB to ShcD PTB domain, we next asked whether TrkB can phosphorylate ShcD and the role of TrkB Y516 in ShcD phosphorylation. As shown in Fig. S1 , ShcD could be phosphorylated by activated TrkB. TrkBM1 is a kinase dead mutant which could not undergo au-http://bmbreports.org tophosphorylation, and this mutant was unable to phosphorylate ShcD. Co-transfection of TrkBM2 and ShcD exhibited almost no detectible phosphorylation of ShcD, indicating that Y516 of TrkB is a critical site for downstream ShcD phosphorylation. These data indicate that TrkB can phosphorylate ShcD.
ShcD mediates MAPK activation
Next, We examined the effects of ShcD on MAPK signaling pathway. Western blot analysis in Fig. 4 showed a slight increased and prolonged activation of MAPK in cells transfected with ShcD compared to those transfected with control empty vector. These observations suggest that ShcD serves as a link between ligand-activated TrkB receptor and MAPK signaling pathway.
It was reported that ShcA is involved in MAPK activation through formation of Shc-Grb2 complex. Once activated by cell-surface receptors, ShcA becomes phosphorylated at three Tyr sites of the central CH1 region, resulting in recruitment of the Grb2-Sos complex and subsequent ras activation. Unlike ShcA, ShcD possesses six Tyr residues in its CH1 domain. We then further deteceted whether ShcD binds Grb2 when phosphorylated by TrkB (see supplemental material Fig. S2 ). The Y6F mutations within CH1 domain were introduced into the ShcD gene by site-directed mutagenesis and this mutant was designated as ShcD 6F (Fig. S2A) . As indicated in Fig. S2B , ShcD could be phosphorylated by TrkB, and additional BDNF stimulation resulted in enhanced ShcD phosphorylation and increased binding to TrkB, further demonstrating that their interaction is dependent on receptor activation and autophosphorylation. Interestingly, the ShcD 6F mutant retained the ability to associate with TrkB although its tyrosine phosphorylation was almost undetectable even in the presence of BDNF. Moreover, ShcD-Grb2 interaction could be detected only in immunoprecipitates prepared from 293T cells stimulated with BDNF but not from nonstimulated lysates; in contrast, mutation of the six tyrosine residues in CH1 domain abolished ShcD binding to Grb2 upon BDNF stimulation. These data indicate that the six tyrosine residues contained within the ShcD CH1 region is required for ShcD phosphorylation by TrkB and subsequent binding to Grb2.
DISCUSSION
In this study, we described the identification and characterization of a substrate of TrkB, ShcD. Our experiments demonstrated direct interaction between ShcD and TrkB, both the PTB and SH2 domains of ShcD are involved in this interaction and the interaction is dependent on receptor tyrosine kinase activity. In contrast, the interaction between ShcA/B/C and Trk receptors is mediated solely through the PTB domain, suggesting differences in how these Shc adapters interact with Trk receptors. We also detected the interacton of ShcD with TrkA or TrkC in yeast two-hybrid assay and found that full-length ShcD bound comparably to the intracellular domains of these three Trk receptors, suggesting that ShcD is a general substrate of Trk family members. This is unlike Dok5, which is a substrate of TrkB/C, but not TrkA (7) .
Mapping experiments indicate that ShcD PTB domain interacts with Tyr516 (within the conserved NPQY motif) of human TrkB in a phosphorylation-dependent fashion. However, we failed to identify the binding sites of ShcD SH2 domain on TrkB because single point mutation of tyrosine residue on TrkB ICD does not affect SH2 binding in yeast two-hybrid assay (data not shown), raising the possibility that SH2 binds at multiple phosphotyrosines on TrkB. This is not unexpected since several PTB or SH2 domain containing adaptors bind to multiple tyrosine residues on certain receptor tyrosine kinase. For example, Grb2 binds three tyrosine residues on TrkA through its SH2 domain, and Shc binds at five tyrosine sites on the PDGFRβ receptor (12) (13) (14) .
Till now all of the four Shc proteins are capable of binding to the three Trk receptors. Upon neurotrophin stimulation, Shc adaptors are tyrosine phosphorylated and associate with Grb2, leading to MAPK activation. There are obvious differences in the temporal and spatial expression of Shc family members during neural development. They may function nonredundantly, contributing differently to the Trk signaling. Besides Shc proteins, there are many other Trk receptor-binding partners, such as Grb2, Numb, Dok5, etc. Due to their differential expression pattern and different binding affinity, apparently, Trk receptormediated interactions with downstream adaptor proteins is far more complex than currently appreciated (15) . These adaptors certainly compete with each other for receptor binding in some cases. The detailed mechanism and biological significance of this interaction remains to be clarified. The mechanism by which Trk receptors signal after neurotrophin activation is incompletely understood.
In our study, the over-expression data showed that ShcD interacts with TrkB and enhances BDNF-induced MAPK activation. TrkB is expressed in both the developing and mature nervous system. Very few TrkB molecules are localized in neuronal cells and most of these TrkB molecules are localized in synapses. ShcD is mainly expressed in mature nervous system, however, its distribution in neuronal cells is not precisely determined. If ShcD is distributed on synapses of neuronal cells, then ShcD may play a direct role in neural system via BDNF-TrkB signaling pathway. Certainly, in this case, other adaptors may also act as downstream effectors of TrkB. If ShcD is not distributed on synapses, then ShcD will not function downstream of TrkB in mature nervous system. Further studies will be needed to elucidate the precise function of ShcD interaction with TrkB in nervous system.
In conclusion, we have identified ShcD as the substrate of TrkB receptor and found that it participates in MAPK activation induced by BDNF. This result provides new insights on ShcD function and that ShcD may play an important role in Trk signaling. Ongoing studies will be directed at determining the role of ShcD in primary cultured neurons and in mouse model.
MATERIALS AND METHODS
Reagents, antibodies and cells
Human recombinant BDNF was purchased from Peprotech. The anti-V5 polyclonal antibody was purchased from Novus. The anti-Flag monoclonal antibody was from Sigma. The anti-Erk, anti-phospho-p44/42Erk MAP kinase and anti-pTyr (PY99) antibody were purchased from Santa Cruz Biotechnology. Human embryonic kidney 293T cells were grown in DMEM with 10% fetal bovine serum (Hyclone). The cells were transfected with Lipofectamine 2000 (Invitrogen) according to the user manual.
Plasmid construction
All the constructs encoding wild type TrkB and TrkB mutants have been described previously (7) . Full-length human ShcD cDNA was isolated from fetal brain cDNA library (Clontech) and cloned into pcDNA3.1-Flag vector. Then the full-length ShcD and truncated forms of ShcD (CH2 domain, PTB domain, CH1 domain and SH2 domain) were subcloned into pACT2 vector, which contains the GAL4 transcriptional activation domain (Clontech). The PTB (aa 180 to 351) and SH2 (aa 524 to 603) domains of ShcD were subcloned into pGEX-6P-1 (Amersham Biosciences) to generate glutathione S-transferase (GST) fusion proteins. pcDNA3.1Flag-ShcD 6F (Y374/5F, Y403F, Y413F, Y424F, Y465F) were generated by using QuikChange Site-Directed Mutagenesis Kit (Stratagene). For image analysis, ShcD cDNA were subcloned into pEGFP-N1 vector.
Yeast two-hybrid assay
The yeast two-hybrid assay was described previously (7) .
GST pull-down assay pGEX6P-1, pGEX6P-ShcD-PTB and pGEX6P-ShcD-SH2 were transformed into E. coli strain Rosetta (DE3). The fusion proteins were expressed and purified according to the manufacturer's instructions. For GST pull-down assays, 293T cells were transiently transfected with pcDNA3.1V5-TrkB/BM1 plasmids. 24 h later, the cells were treated with 100 ng/ml BDNF for 10 min and lysed. The cell lysates were cleared and incubated with the same amount of GST, GST-ShcD-PTB, GST-ShcD-SH2 fusion proteins at 4 o C for 2 h. The beads were washed and boiled in the presence of SDS-PAGE loading buffer. Protein samples were analyzed by SDS-PAGE and Western blot.
Co-immunoprecipitation
293T cells were transiently co-transfected with pcDNA3.1V5-TrkB and pcDNA3.1Flag-ShcD or pcDNA3.1V5-TrkBM1 and pcDNA3.1Flag-ShcD, then stimulated with 100 ng/ml BDNF for 10 min. The cells were lysed in 750 μl lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 120 mM NaCl, 0.5% NP-40, 10% glycerol, 1 mM Na3VO4, 25 mM NaF) containing protease inhibitors. Cell lysates were precipitated with anti-Flag antibody and analyzed by Western blotting with the indicated antibodies.
Fluorescence microscopy
Transfected 293T cells were fixed with 4% paraformaldehyde for 20 min at room temperature, then washed with phosphate-buffed saline (PBS) for 3 times and stained with DAPI. Coverslips were mounted and observed under Leica confocal microscope.
